Effects of resistance training on endothelial progenitor cells in young smokers: a pilot study by Dam, Andrew
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Effects of resistance training on
endothelial progenitor cells in
young smokers: a pilot study
https://hdl.handle.net/2144/16135
Boston University
   
  
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
EFFECTS OF RESISTANCE TRAINING ON ENDOTHELIAL    
 
PROGENITOR CELLS IN YOUNG SMOKERS: A PILOT STUDY 
 
 
 
 
by 
 
 
 
 
ANDREW T. DAM 
 
B.S., University of California Irvine, 2013 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2015
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 by 
 ANDREW T. DAM 
 All rights reserved
   
  
Approved by 
 
 
 
 
First Reader   
 Theresa A. Davies, Ph.D. 
 Assistant Professor of Medical Sciences & Education 
 Director, M.S.in Oral Health Sciences Program 
 
 
 
Second Reader    
 Eliza Wu, Ph.D. 
 Postdoctoral Scholar, School of Nursing  
 University of California, Los Angeles 
              
 
 
 
 
  iv
DEDICATION 
 
 
 
 
I would like to dedicate this work to my loving parents, for supporting all of my 
endeavors, no matter how foolish or asinine. I would also like to give special 
thank Dr. Theresa Davies for helping me through the writing submission process.  
 
 
  v
 
EFFECTS OF RESISTANCE TRAINING ON ENDOTHELIAL  
 
PROGENITOR CELLS IN YOUNG SMOKERS: A PILOT STUDY 
 
 
ANDREW T. DAM 
 
 
ABSTRACT 
Background: Research has shown that cigarette smoking is linked to endothelial 
dysfunction, which represents a key early step in the development of 
atherosclerosis. This association between endothelial dysfunction and 
atherosclerosis also suggests that the status of an individual’s endothelial 
function can be a potential indicator of a cardiovascular health. To better 
understand endothelial dysfunction, researchers have started to quantify 
peripheral circulating endothelial progenitor cells as effective biomarkers for 
cardiovascular risks. Many cardiovascular disease risk factors are immutable; 
however, recent studies have recognized resistance training as a viable strategy 
for cardiovascular disease prevention. Furthermore, there are only a few studies 
that focus on endothelial progenitor cells as a biomarker to investigate the effects 
of resistance training on cardiovascular health. This pilot study explored the 
effects of resistance intervention on circulating endothelial progenitor cells in both 
women and men smokers. 
 
Methods: A group of 12 healthy young smokers were randomized into a 12-
week RT or control group. Measurements were taken once at the beginning of 
  vi
the study and once again at the end of the study (week 13).  Participants were 
assessed for any changes from baseline in endothelial progenitor cell count, 
nicotine dependence and relative strength.    
 
Results: Average endothelial progenitor cell count decreased in both RT and 
control from baseline. However, RT saw a larger decrease in CD34+, CD133+, 
and KDR when compared to control. We observed a decrease in the mean 
Fargerstrom Test for Nicotine Dependence score for RT, while control saw an 
increase from the average baseline score. We also noted an increase in average 
relative strength from RT participants, while relative strength slightly decreased in 
control. There were no significant changes in body weight or body mass index in 
both groups.  
 
Conclusion: This is the first study to investigate the effects of RT on EPC count 
in young smokers. The findings from this study do not suggest a positive 
relationship between RT intervention and EPC count. Results did indicate that 
RT had a lower nicotine dependence compared with control following 
intervention, which provides more evidence for RT as an adjunctive strategy for 
smoke cessation.  However, due to the low sample number in this study, an 
adequately powered experimental design is warranted. 
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INTRODUCTION 
 
Tobacco Use 
A landmark report published in 1964 by the Surgeon General’s Advisory 
Committee on Smoking and Health established the link between smoking, lung 
cancer, and other lung diseases as well as possible correlation between smoking 
and other cardiovascular diseases1. The 1964 report had wide effects across the 
world and led to more public awareness of the adverse effects of cigarette 
smoking as well as greater efforts to change policies on advertising, warning 
labels, and restrictions on tobacco industries. Since publication of the report by 
the Surgeon General’s Advisory Committee on Smoking and Health in 1964, 
cigarette consumption has declined every year1. Public awareness on the 
consequences of cigarettes also shifted since the report, and the link between 
cigarettes and its harmful effects have well established itself in the domain of 
public knowledge. In spite of these great accomplishments, the tobacco epidemic 
is still one the greatest public health concerns ever encountered. It is estimated 
that there are currently over 1 billion smokers worldwide, or about 16% of the 
global population2,3. Moreover, cigarette smoking continues to be the leading 
cause of preventable deaths in the United States, causing about 443,000 
premature deaths every year4. The World Health Organization (WHO) published 
a report on the global tobacco epidemic estimating the prevalence of smoking in 
different countries, as shown in Table 11.  
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Table 1: Estimates of the prevalence of current cigarette smokers for selected countries of 
the World Health Organization, 2009. Estimates are standardized to age distribution and based 
on whether smoking at the time of survey was daily or non-daily. (Source modified from the U.S. 
Department of Health and Human Services1) 
 
 
 
 
 
The addictive nature of nicotine makes cessation attempts difficult for smokers, 
with only about 4% to 7% of people being able to successfully quit smoking at 
any given attempt without the use of medication5. According to the Center for 
Disease Control and Prevention (CDC), there are over 7,000 chemicals and 
compounds in cigarette smoke6. Of these compounds and chemicals, hundreds 
are toxic to humans and more than 70 have been identified as carcinogens7. The 
carcinogens of most concern are polycyclic aromatic hydrocarbons (PAH), N-
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nitrosamines, aromatic amines, 1,3-butadiene, benzene, aldehydes, and 
ethylene oxide because of carcinogenic potency and levels found in cigarette 
smoke8. Furthermore, the tobacco industry has devoted a large amount of 
research and developments to the use of additives to cigarettes, and have 
acknowledged using 599 different cigarette additives9. Although tobacco 
companies claim that these additives are used to reduce the harshness and 
improve the taste of cigarettes, one study has shown that over 100 of these 
additives can enhance the addictiveness of cigarettes, and mask symptoms and 
illnesses linked to smoking behavior10,11. Figure 111 shows a summary of the 
pharmacological and chemical effects of cigarette additives. 
  4
 
 
 
Figure 1: Summary of the Pharmacological and Chemical Effects of Cigarette Additives. 
ETS = environmental tobacco smoke; GVL = gamma-valerolactone; AT = ammonia technology; 
NH3 = ammonia; NH4OH = ammonia hydroxide; CNS = central nervous system; DAP = 
diammonium phosphate; MAP = monoammonium phosphate. (Source from Rabinoff et al., 
200711) 
 
Tobacco and Cancer  
Smokers tend to have a much higher chance of developing cancers when 
compared to non-smokers. According to WHO, lung cancer is the most common 
form of cancer worldwide12. It is estimated that smoking contributes to 80%-90% 
of all lung cancers, with over 150,000 Americans died from lung cancer alone in 
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201413. Compared to non-smokers, men and women who smoke are 23 times 
and 13 times more likely to develop lung cancer, respectively13. Secondhand 
smoke also causes premature death and disease in those who do not smoke. 
For example, non-smokers who report being exposed to secondhand smoke at 
home or work increase their chance of developing lung cancer by 20%-30%9.  
Although lung and cardiovascular diseases are commonly associated with 
smoking, there are some cancers not normally associated with smoking that are 
more likely in smokers such as stomach, pancreatic, and bladder cancer14.  
 
Many components of cigarette smoke, when metabolized or transformed, may 
lead to cancer, as show in Figure 21. 
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There are some constituents of cigarettes or their metabolites that bind to growth 
receptors, which may activate secondary messenger pathways that can lead to 
carcinogenesis1. Furthermore, cigarette smoke also contains carcinogens which, 
while do not cause cancer themselves, may enhance cigarettes carcinogenic 
effects1. Epidemiologic studies have also investigated whether the risk of lung 
cancer death in smokers has changed over time. In one study by The American 
Chemical Society (ACS), results from two prospective cohort studies conducted 
over 20 years apart were compared in order to assess the effects of changes in 
the composition and design of cigarettes on the American smoker. Their findings 
showed that the risk of lung cancer deaths increased dramatically in the second 
cohort after controlling for measured differences in the duration and amount of 
cigarettes smoked per day between the smokers in the two studies15. 
Interestingly, the rate of lung cancer mortality remained unchanged for never 
smokers in this study, suggesting that the increased risk observed in smokers 
were unlikely to have occurred due to other risk factors for lung cancer in the 
general population15. The results from these studies have suggested that the 
changes in composition and design of cigarettes since the 1950s are responsible 
for the increased risk of lung cancer mortality15. Figure 315 shows the analysis of 
the two studies for men and women smokers and never smokers. 
  8
 
Figure 3: Death Rates from all Lung Cancers, Cancer Prevention Study I (CPS-1) and 
Cancer Prevention Study II (CPS-II), 1959-1965 and 1982-1988. All data was adjusted for age, 
duration of smoking, and number of cigarettes smoked per day. Women smokers saw a larger 
increase in rate compared to male smokers by the end of the Cancer Prevention Study II. Each 
data point represents the death rate measured at the end of the six year interval for both studies. 
(Source modified from Thun, et al., 199715) 
 
 
Cardiovascular Disease 
Cigarette smoking and exposure of nonsmokers to tobacco smoke is known to 
increase the chances of developing cardiovascular disease (CVD)1. CVDs are 
the leading cause of death worldwide, causing over seven million deaths in 2008, 
or about 13% of total global mortality16. Table 217 lists the prevalence of CVDs in 
the United States in 2008. The term “cardiovascular disease” usually refers to 
conditions affecting the heart that can lead to myocardial infarction, or heart 
attack. These include, but are not limited to, hypertension, atherosclerosis, 
coronary heart disease, congenital heart defects, and arrhythmias.  
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Table 2: Prevalence of Cardiovascular Diseases in the United States, 2008. AMI= acute 
myocardial infarction; CHD= coronary heart disease. (Source modified from The National Heart, 
Lung, and Blood Institute, 201217) 
 
 
 
 
The single most important risk factor for developing CVDs is age, which poses as 
a big public health concern in the near future as the mean age of the population 
continues to increase in industrialized countries through unprecedented 
advances in disease prevention, diagnostics, and treatment18. Some factors for 
CVD are immutable: age, gender, and family history1. In spite of this, CVD is 
common among both genders and all ethnic/racial groups1. The age-adjusted 
annual death rates for CVD have continued to remain higher for men, and are 
highest among non-Hispanic Blacks across all age groups1. Figures 417 and 517 
depict the death rates for heart diseases in men and women, respectively, by age 
and race/ethnicity.  Although some risk factors are unchangeable, many 
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important are modifiable through lifestyle changes, e.g., limiting tobacco use, 
exercise, healthy eating, and avoiding excessive alcohol consumption.  
 
 
 
 
 
Figure 4: Death Rates Caused by Heart Diseases in Men by Age and Race/Ethnicity. aNon-
Hispanic. (Source modified from The National Heart, Lung, and Blood Institute, 201217) 
  11
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Death Rates Caused by Heart Diseases in Women by Age and Race/Ethnicity. 
aNon-Hispanic. (Source modified from The National Heart, Lung, and Blood Institute, 201217) 
 
 
Research has shown that the top two leading preventable causes of death in the 
United States can be linked to tobacco use and obesity19. According to a report 
published by the U.S. Department of Health and Human Resources, two thirds of 
CVD deaths are attributed smoking in both men and women1. Although the 
absolute rate of CVD is higher in men than women, the increments in risk from 
smoking yields larger relative risks for women compared to men, suggesting that 
a high proportion of CVD in women are attributed to smoking (the female/male 
ratio being 1.25)1. Moreover, the amount of cigarettes smoked per day is an 
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important factor for determining relative risk (RR) of mortality, with a positive 
correlation shown between amount of cigarettes smoked per day and RR1.  
 
Smoking and Endothelial Function 
The cells that line blood vessels make up the vascular endothelium. The 
endothelium is central for normal cardiovascular function, by promoting blood 
vessel dilation, thrombosis, and exerting anti-inflammatory effects1. When 
endothelial function is impaired, the activation of chemical signals within the 
endothelium is compromised and is characterized by a proinflammatory, 
procoagulatory, and proproliferative disease state20.  Figure 620 is an overview of 
the various factors affecting the endothelium and the consequences of its 
dysfunction.  
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Figure 6: Mechanism of Endothelial Dysfunction and the Resulting Consequences. 
Cigarette smoke falls under traditional risk factors and is a major contributor to endothelial 
dysfunction. Vascular damage will lead to atherosclerosis and eventually cardiovascular disease, 
the number one cause of mortality worldwide (Modified from Hadi et al., 200520). 
 
 
One important mechanism by which the vascular endothelium operates is 
through the production of nitric oxide (NO). NO is a potent inhibitor of both 
leukocyte and platelet aggregation and adhesion21. This offers protection from 
fibrous plaque formation as well as white cell adherence, events that are 
characteristic of atherosclerosis21. 
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Cigarette smoke and its constituents form free radicals and reactive-oxygen 
species (ROS), which reduced the availability of NO and promotes endothelial 
dysfunction21. Endothelial nitric oxide synthase (eNOS) is responsible for much of 
the NO production in the vasculature21. Interestingly, eNOS expression has been 
shown to increase rather than decrease in response to cardiovascular risk 
factors22. The increase in eNOS is likely due to the increased presence of ROS, 
which enhances eNOS expression through transcriptional and posttranscriptional 
mechanisms22. In spite of this increased expression, ROS react with the NO 
produced by eNOS and converts the functional NO into another ROS, causing 
further oxidative stress on the vasculature22. Figure 721 depicts the possible 
mechanism through which cardiovascular risk factors cause endothelial 
dysfunction.  
  15
 
 
 
Figure 7: Mechanism by Which Cardiovascular Risk Factors Lead to Endothelial 
Dysfunction. NADPH oxidase is upregulated in parallel with eNOS in response to cardiovascular 
risk factors. Their respective products form to create ONOO-, causing oxidative damage to eNOS 
and producing more ROS. (Source modified from Forstermann et al., 200621) 
 
 
Endothelial Progenitor Cell Overview 
Endothelial cells make up the monolayer of cells lining the vascular endothelium. 
Following an acute stress injury of the vascular endothelium, the endothelial cells 
are destroyed by programmed cell death. At this point, regeneration of the 
endothelium is important to mitigate atherosclerotic plaque development23. 
Because endothelial cells are terminally differentiated, another type of cell is 
needed for endothelial repair. Many studies have shown that endothelial 
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progenitor cells (EPCs) fulfill this role23. Figure 823 shows a depiction of how 
EPCs respond to damaged endothelium. Endothelial progenitor cells are a rare 
subset of circulating, bone marrow-derived cells that are involved in postnatal 
neovascularization and neoendotheliazation following endothelial injury24. EPCs 
have the potential to proliferate and to differentiate into endothelial cells, 
however, there is still debate as to how the damaged endothelial cells 
communicate with EPCs to initiate repair23. Lower counts of EPCs are associated 
with cardiovascular risk factors and vascular dysfunction, and experiments have 
shown that diminshed EPC counts are linked to impaired regenerative potential25. 
Table 324 shows various factors that influence the number of circulating EPCs. 
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Figure 8: Mobilization and Repair of Damaged Endothelium. Circulating EPCs home in on the 
site of vascular injury through an unknown intracellular signaling pathway. Once at the 
endothelium monolayer, EPCs may differentiate into mature endothelial cells or transdifferentiate 
into vascular smooth muscle cells. (Source from Hristov et al., 200323).  
 
 
 
 
 
Table 3: The Pathological and Physiological Factors that Have Been Found to Affect the 
Number of EPCs in Systemic Circulation. Patients with risk factors for ischemic cardiovascular 
disease have shown to have a rapid increase in circulating EPCs. In contrast, those suffering 
from limb ischemia and acute myocardial infarction show a rapid increase in circulating EPCs 
Modified from Hristov et al., 200323) 
 
 
Conditions or Factors Changes in Number of EPCs 
    Cardiovascular risk factors Decreased 
    Limb Ischemia Increased 
    Acute myocardial Infarction Increased 
    Vascular Trauma Increased 
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Endothelial Progenitor Cell Characterization 
In general, EPCs are characterized by the expression of three biomarkers: 
CD133+, CD34+, and vascular endothelial growth factor receptor-2 [also termed  
receptor, or (KDR)]26. Cells that display a mix of CD133+/CD34+/KDR, but do not 
express vascular endothelial cadherin (VEC) and von Willebrand factor (vWF) 
are typically localized in the bone marrow and not the peripheral circulation23. 
VEC is expressed in mature EPCs and endothelial cells (EC), and play a role in 
the cohesion and organization of intercellular junctions within the endothelium27. 
VEC is also necessary for proper vascular development by maintaining newly 
formed vessels28. vWF plays an important role in blood coagulation and is 
expressed in mature EC and EPCs. The more mature EPCs found circulating in 
the peripheral circulation will be show a positive expression for CD34+ and KDR, 
but will have lost the expression of CD13323. Once EPCs begin to differentiate 
into more mature ECs, they begin to show a high expression of KDR, VEC, and 
vWF, but no expression of CD13323. Therefore, it seems as though the loss of 
CD133, and expression of VECand vWF is important in the transformation of 
circulating EPCs into more mature ECs23. This transformation is thought to occur 
while EPCs are still in circulation, but there is still debate as to exactly when 
EPCs fully differentiate into mature endothelial cells in vivo23.  
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Resistance Training 
Resistance training (RT) is a form of physical exercise that involves the use of 
any form of resistance to induce skeletal muscle contraction, which helps 
improve strength, size of skeletal muscle, metabolism, and overall health29. RT 
commonly relies on the technique of progressively increasing the force output on 
target muscle groups through the use of a variety of equipment and exercises. 
The intensity, volume, and frequency of an exercise can be manipulated in order 
to achieve the desired changes in an individual. Lack of physical activity is 
associated with increased chances of developing CVD in a positive dose-
response fashion30. Physical inactivity promotes the release of bioactive 
mediators that alters coagulation and fibrinolysis, which increase the likelihood of 
endothelial dysfunction and atherosclerosis leading to CVD20. RT has been 
shown to assist the body in burning calories via an increase in lean body mass 
and basal metabolism31. Thus, resistance training exercise is a viable strategy for 
primary and secondary cardiovascular disease–prevention. Table 431 
summarizes the benefits of resistance training. RT also has potential therapeutic 
uses for smokers. In pilot study examining RT as an aid to smoking cessation, 
results showed that the RT group had a higher abstinence rate compared with 
the control, which suggests that has RT can be used as a adjunctive strategy in 
smoke cessation32.  
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Table 4: Comparison of Aerobic Endurance Training with Resistance Training on Various 
Health Variables. ↑ indicates values increase; ↓, values decrease; ↔, values remain unchanged; 
↑ or ↓, small effect; ↑↑ or ↓↓, medium effect; ↑↑↑ or ↓↓↓, large effect; LBM, lean body mass; HDL, 
high-density lipoprotein cholesterol; and LDL, low-density lipoprotein cholesterol. (Source 
modified from Pollock et al., 200031) 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Response 
Bone mineral density ↑↑ 
% Fat ↓ 
LBM ↑↑ 
Strength ↑↑↑ 
Glucose metabolism   
Insulin response to 
glucose challenge 
↓↓ 
Basal insulin levels ↓ 
Insulin sensitivity ↑↑ 
Serum lipids   
HDL ↑↔ 
LDL ↓↔ 
Resting heart rate ↔ 
Stroke volume, 
resting and maximal 
↔ 
Blood pressure at 
rest 
  
Systolic ↔ 
Diastolic ↓↔ 
V̇o2max ↑↔ 
Submaximal and 
maximal endurance 
time 
↑↑ 
Basal metabolism ↑↑ 
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METHODS 
Study Participants 
 
 
Subjects were recruited and screened using print advertisements, flyers, and 
internet postings from the West Los Angeles community. Twelve young adults 
(age 18-5) male and female light/moderate smokers (100 cigarettes lifetime 
minimum, 15 cigarettes per month minimum) were randomly assigned to either 
the resistance training group or control. Potential participants were excluded if 
they had documented CVD, cardiac arrhythmia or electrocardiogram (EKG) not 
conducive to arterial stiffness indices assessment, used medications that 
influence cardiovascular function, body composition or insulin indices in the prior 
6 months, or exercised vigorously > 2 times a week. Patient data were excluded 
from the study if the participant did not complete the study. 
 
On the day of testing, subjects fasted overnight and abstained from alcohol, 
caffeine, and vitamin supplements for 24 hours prior to the measurement. 
Subjects were asked not to engage in any moderate to vigorous physical activity 
within 36 hours of the visit. Smokers were also told to refrain from smoking after 
midnight on the day of scheduled visiting, with the time of their last cigarette 
recorded. Female visits were performed in the early follicular phase (days 1-7) of 
their menstrual cycle. All of the study protocols were approved by the University 
of California, Los Angeles (UCLA) Institutional Review Board and were 
performed according to the Declaration of Helsinki.  
  22
 
Smoking Dependence Assessment 
To verify smoking dependence status, smokers were assessed using the 
Fagerström test for nicotine dependence (FTND). Figure 9 explains the 
guidelines for the Fagerström scoring interpretation. A score of 0-3 is considered 
to be a low level of smoking dependence, and is characterized by a mild physical 
dependence, potential benefit from professional counseling, and no 
recommendation of pharmacotherapy at initial assessment. A score of 4-6 points 
is characterized by medium physical dependence, a benefit from professional 
counseling, and possible treatment with pharmacotherapy after initial 
assessment. A score of 7-10 points is considered to be a high level of 
dependence. Participants scoring in this range show strong physical 
dependence, require professional counseling, and are recommended to undergo 
pharmacotherapy if suitable.  
 
 
 
 
Figure 9: Fagerström Score Guideline. The level of smoking dependence was measured by the 
Fargerstrom questionnaire during visits 1 and 2. 
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Resistance Training  
Training occurred at the John Wooden Recreation Center (UCLA). Participants 
engaged in three supervised 60-minute resistance-training sessions per week for 
twelve weeks. The training was split into three linear periodization 
phases.  During phase 1 (week 1-2), participants were required to complete two 
sets of 12-15 repetitions for each exercise at their repetition maximum (RM). 
Repetition maximum is defined as reaching volitional fatigue/failure within the 
given repetitions. In phase 2 (week 3–7), participants completed three sets of 8–
12 repetitions at their RM, and in phase 3 (week 8–12), participants completed 
six to eight repetitions at 100% at their RM. Weight of the exercises were 
increased to maintain the prescribed training intensity. Participants cycled 
between two workout regimens during their training sessions, which occurred on 
three nonconsecutive days per week. Workout 1 consisted of dumbbell (DB) 
squat, cable row, DB front lunge, DB row, barbell (BB) deadlift, DB triceps 
extension, and DB curls. Workout 2 consisted of DB step-up, BB chest press, 
machine squat, DB overhead press, DB incline chest press, DB side raise, DB 
reverse fly, and abdominal crunches33. A certified personal trainer supervised all 
training sessions.  
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Before maximal strength testing, participants warmed up each muscle group by 
performing 8-10 repetitions of BB bench press, 45° incline leg press, and 
machine-seated row with weight equal to 40-60% of their estimated one 
repetition maximum (1-RM). Following the warm-up, maximal strength testing 
was carried out using the same exercises as during the warm-up but performed 
at there 100% 1-RM. In order to determine each participants 1-RM, weight was 
increased progressively while decreasing the repetitions until the participant 
could safely attempt an estimated 1-RM for each exercise. Participants were 
allowed 3–4 min of rest between all sets. All participants performed two maximal 
strength tests, one immediately preceding the first training session and the 
second immediately preceding their penultimate training session. All participants 
were asked not to perform RT exercises beyond the supervised sessions. 
Relative strength (RS) measures were calculated by dividing each measure 
[kilograms (kg)] by participant body weight (kg)33.  
Outpatient Visit Procedures 
The measurements were taken from the participants at baseline (visit 1) and at 
the end of the study on week 13 (visit 2). Each measurement period consisted of 
two outpatient visits. The first visit was at the UCLA Clinical and Translation 
Research Center (CTRC). Participants had their CTRC outpatient visit within 72 
hours after the last training session in order to control for any acute effects of the 
training program due to RT. The subsequent same-week Saturday visit occurred 
96-120 hours following the last training session. Before each visit, participants 
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were reminded to: 1) avoid all moderate-to-vigorous physical activity 24 h before 
testing and 2) abstain from all food and drink (except water) for ~12 h before 
each visit. Verbal confirmation of adherence to the aforementioned criteria was 
obtained immediately before all testing33. 
Outpatient Visit 1 
Participants were instructed to arrive at 7:30 AM on the day of the visit, with each 
visit lasted approximately 3.5 hours. First, a physician administered a 12-lead 
ECG to potential participants in order to assess whether they were healthy 
enough to participate in exercise training. Measurements were carried in 
duplicates in all participants to ensure accuracy. Fasting blood samples were 
collected, and serum was separated and stored at −80°C until assayed. 
Subsequently, a two-hour oral glucose tolerance test (OGTT) was performed. 
Outpatient Visit 2 
The body compositions of participants were determined by a dual-energy X-ray 
absorptiometry scan (QDR 4500 fan beam X-ray densitometer; Hologic, Bedford, 
MA). Glycated hemoglobin A1c (HbA1c) was measured via a DCA Vantage 
analyzer (Siemens Medical Solutions USA, New York, NY), and a physical 
activity questionnaire [International Physical Activity Questionnaire (IPAQ)] was 
administered33. After body composition scans were completed, a physician 
performed a muscle biopsy on the left vastus lateralis muscle. 
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Quantification of Endothelial Progenitor Cells (EPC) 
Blood was collected from participants once before the start of the study and once 
after the study was completed. EPC were quantitated using a novel cytometry 
protocol we developed. Whole blood (10mL) was collected and erythrocytes were 
lysed. Following 10 min incubation, leukocytes were isolated by density gradient 
centrifugation, and then subsequently washed. A 7-color antibody panel was 
used to stain the population of leukocytes: anti-CD34-PE-Cy7, anti-CD-3, anti-
CD-19, anti-CD-33, anti-FITC-CD45, anti-CD133-PE, and anti-APC-KDR. 
Acquired pellets were incubated with mouse serum for 20 min. Following a 45-
min incubation, samples and fluorescence minus one tubes (FMOs) were 
washed with staining buffer (PBS + 3%FBS, 0.5% bovine serum albumin and 1% 
sodium azide). Propidium iodide was added for discrimination of dead cells. 
Samples were acquired on a BD LSR II flow cytometer. The mononuclear cell 
fraction was identified by forward scattering and low side scattering. A sequential 
gating strategy selecting live mononuclear cells with low expression of CD45 led 
to quantification of CD34+, CD133+, KDR+ and CD133+KDR+ events.  
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RESULTS 
 
Measurements Within RT Group 
The mean age was 27.1 years old (SD=6.6) in the RT group. Participants scored 
an average of 4.0 (SD=2.82) on the FTND at baseline (Table 5). We observed a 
54% decrease (P=0.19) in FTND score after resistance training intervention in 
RT. The average RS at baseline was 3.89 (SD=0.69) and increased 23% to 4.77 
(SD=1.03) in visit 2 (Table 6). Average weight at baseline was 71.9 kg (SD=9.3), 
and there was no significant increase in weight measured in visit 2. The mean 
body mass index (BMI) was 25.9 kg/m2 (SD=4.1) during baseline and 26.2 kg/m2 
(SD=3.9) during visit 2.  
 
Table 5: Achieved Fagerström Test for Nicotine Dependence Score in Resistance Training  
during Visit 1 and Visit 2. 
 
 RS Measurements  
 Visit 1 Visit 2 
Mean 3.89 4.77 
SD 0.69 1.03 
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Table 6: Relative Strength Measurements in Resistance Training during Visit 1 and Visit 2. 
 
 
We defined circulating EPCs as cells that express CD34+, CD133+, and KDR+. 
There was a decrease in the absolute number of circulating CD34+, KDR+, and 
CD133+ after RT intervention. Furthermore, we observed a decrease in the 
percentages of KDR+ of CD34+ (%KDR+/CD34+) and CD133+ of CD34+ 
(%CD133+/CD34) from baseline. Table 7 is a summary of the observed changes 
in EPCs in peripheral blood of RT.  
 
Table 7: Summary of Changes in Endothelial Progenitor Cells of Resistance Training. 
Values are expressed as means with ± standard error of the mean (SEM) 
 
 
 FTND Measurements  
 Visit 1 Visit 2 
Mean 4.00 2.17 
SD 2.83 2.56 
Outcomes Visit 1 Visit 2 Changes P-value 
CD34+ (/ml blood) 1424.83±483.69 485.33±114.32 -939.50 0.09 
CD133+ (/ml blood) 675.83±218.21 176.16±39.28 -499.66 0.08 
KDR (/ml blood) 11.16±4.28 2.33±0.80 -8.83 0.12 
%CD133+of CD34+ 48.32±2.52 41.02±7.11 -7.29 0.21 
%KDR+ofCD34+ 0.68±0.18 0.50±0.13 -0.18 0.49 
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Measurements Within Control 
The average age of participants in the control group was 27.1 years old 
(SD=5.2). Average weight at baseline was 82.0 kg (SD=16.0), with no significant 
change in visit 2. Average BMI at baseline was 27.6 kg/m2 (SD=5.9) and 27.2 
kg/m2 (SD=6.2) at the end of the study. The mean FTND score at baseline was 
2.83 (SD=2.64) and increased 18% to 3.33 (SD=2.58) by visit 2 (Table 8). The 
average RM score at baseline was 5.09 (SD=0.54) and 4.58 (SD=1.05) at visit 2 
(Table 9).   
 
Table 8: Achieved Fagerström Test for Nicotine Dependence Score in Control During Visit 
1 and Visit 2 
 
 FTND Measurements  
 Visit 1 Visit 2 
Mean 2.83 3.33 
SD 2.64 2.58 
 
 
Table 9: Repetition Maximum Measured in Control during Visit 1 and Visit 2 
 RS Measurements  
 Visit 1 Visit 2 
Mean 5.09 4.58 
SD 0.54 1.05 
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There was a mean decrease in CD34+, CD133+, and KDR from baseline 
measurements. Furthermore, we observed a decrease in %CD133+/CD34+ and 
%KDR/CD34+. Table 10 shows a summary of the changes in EPC 
measurements in the control group. 
 
Table 10: Summary of Endothelial Progenitor Cell Changes in Control. Values are 
expressed as means with ±SEM. 
 
Outcomes Visit 1 Visit 2 Changes P-value 
CD34+ (/ml blood) 744.50±175.34 361.50±85.53 -383 0.18 
CD133+ (/ml blood) 313.66±54.76 119.83±58.37 -193.83 0.09 
KDR (/ml blood) 12.83±7.29 3.00±1.61 -9.83 0.25 
%CD133+ofCD34+ 47.16±4.38 26.15±9.14 -21.01 0.05 
%KDR+ofCD34+ 1.27±0.57 0.89±0.31 -0.38 0.41 
 
 
Measurements Between Resistance Training and Control 
RT had a 91% mean increase in CD34+(/ml of blood) compared with control at 
baseline. CD133+ count (/ml of blood) was also 115% higher in RT compared to 
control at baseline. CD133+ and CD34+(/ml of blood) were reduced in both 
groups from baseline, with CD34+ (/ml of blood) decreasing by an average of 
66% in RT and 51% in control (OR 2.5, 95% CI= 0.16-38.60), as shown in Figure 
10. As illustrated in Figure 11, we observed a mean decrease in CD133+(/ml of 
blood) by 74% in RT compared to 62% in control (OR 2.5, 95% CI= 0.16-38.60).  
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Figure 10: CD34+ Measurements in Resistance Training Versus Control During Visit 1 and 
Visit 2. Data end points are depicted as average values collected at each visit. 
 
 
 
Figure 11: CD133+ Measurements in Resistance Training Versus Control during Visit 1 and 
Visit 2. Data end points are depicted as average values collected at each visit. 
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The average KDR amount (/ml of blood) was 13% higher at baseline in control 
compared to RT. In visit 2, there was a similar decrease in measured KDR (/ml of 
blood) for both groups, with a decrease by 77% in control and 79% in RT (OR 
10.0, 95% CI= 0.64-154.40). Figure 12 illustrates the comparison of KDR 
measurements at baseline and visit 2 for RT and control.  
 
 
 
Figure 12: KDR Measurements in Resistance Training and Control at Visit 1 and Visit 2. 
Data end points are depicted as average values collected at each visit. 
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0.002 to 2.244). Based on the FTND scoring guidelines, 4 participants in RT 
were considered to have low nicotine dependence (achieving a score of 0-3 on 
FTND questionnaire), while 2 of the participants were considered to have high 
nicotine dependence (achieving a score of 7-10 on FTND questionnaire) at 
baseline. Furthermore, control had 4 participants with low nicotine dependence, 1 
with medium nicotine dependence, and 1 with high nicotine dependence at 
baseline. By the assessment in visit 2, 4 of the 6 participants in RT continued to 
have low nicotine dependence, while 2 had become medium nicotine dependent. 
In the control group at visit 2, 3 participants were low nicotine dependent, 2 were 
medium nicotine dependent, and 1 was highly nicotine dependent. Figure 13 
depicts the average achieved FTND score for RT and control at baseline and 
visit 2. 
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Figure 13: Average Fagerström Test for Nicotine Dependence Score Achieved by 
Resistance Training and Control at Visit 1 and Visit 2. 
 
Following RT intervention, participants in RT showed a 22% mean increase in 
RS compared with a 10% decrease in control (OR 0.138, 95% CI= 0.005-3.627). 
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DISCUSSION 
 
The implications based on the results from this study do not suggest that there is 
a positive correlation between RT intervention and EPC count in young smokers. 
It should be noted that EPC count decreased in both RT and control from 
baseline. There are several possible explanations for how atherosclerotic risk 
factors can influence the number of EPCs. One scenario might be an increased 
apoptosis of premature progenitor cells. For example, it has been shown that 
immature EPCs are sensitive to angiostatin, which is a naturally occurring protein 
in humans, and induces apoptosis in CD34+ EPCs34. Another possible scenario 
is that participants continued to smoke throughout the study. Smoke cessation 
was not a part of the inclusion criteria for this study (with the exception of visit 
day 1 and 2), therefore the reduced EPC count in both groups might be 
explained by the oxidative stress caused by smoking, which is a well-established 
inducer of apoptosis35. Of the three markers to identify EPCs, KDR experienced 
the largest proportional decrease from baseline compared to CD34+ and 
CD133+. The reduction in KDR may be an important event in the overall 
decrease of circulating EPCs, as seen in our study. KDR is mediated by a 
signaling protein called vascular endothelial growth factor (VEGF), which is 
involved with vasculogenesis and angiogenesis36.  VEGF induces mobilization of 
EPCs towards vascular injury; however, EPCs in smokers show an impairment of 
chemotaxis despite the presence of VEGF24. These findings suggest that 
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cigarette smoking reduces EPCs mobility, possibly through a decreased 
expression of KDR. Therefore, the proportionally larger decrease in KDR 
observed in our study may offer another explanation for the overall decrease in 
the total EPC count for both RT and control.  
 
Limitations 
An important limitation to this study was the small sample size. However, some 
of our findings are consistent with previous work on endothelial dysfunction and 
exposure to cigarette smoke37. Therefore, a future study with an adequately 
powered experimental design is warranted. Moreover, we were unable to match 
for age, gender, and smoking status in our control group due to the low sample 
size. This would inevitably introduce confounding variables, which is reflected by 
the relatively large confidence intervals reported in our study.  
 
Another possible limitation to our study was how we chose to define circulating 
EPCs. The use of EPCs as a biomarker is still relatively new, and their specific 
functions are still unknown. Furthermore, there has yet to be a single biomarker 
identified that can accurately recognize a circulating EPC in vivo. Because of 
this, there are various definitions and characterizations of true EPCs. Our 
methods relied on identifying three surface markers (CD133+, CD34+, and KDR). 
However, CD34+ has also been shown to be present on non-hematopoietic cells 
such as muscle satellite cells, corneal keratocytes, interstitial cells, and epithelial 
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progenitors38. In spite of this, CD34+ is still widely used as one of markers for 
EPCs. Therefore, there should be agreement in the scientific community on the 
characterization of EPCs and its subtypes. This will allow for a more systematic 
approach to understanding the role of EPCs. 
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Physical Medicine & Rehabilitation Department 
Kim D. Thai, SCPMG Regional Chief Physician, PM&R 
Shadow/ Volunteer                                  May 2014- Present 
Kaiser Permanente, Baldwin Park, CA 
• Exposed to manual medicine techniques that emphasize myofascial 
pain, e.g., myofascial release on patients with chronic and acute pain. 
• Assist Dr. Kim in performing Pain Questionnaires Surveys for his lower 
back pain research 
• Gained a better understanding of the physical and emotional needs 
required from those suffering from chronic and acute pain 
• Help Dr. Kim administratively by assisting his patients make and confirm 
future appointments 
• Work alongside team of physical and occupational therapists, 
psychologists, and nurses 
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LEADERSHIP 
 
Phi Kappa Psi Fraternity                                                  Sept. 2009 -June 2013  
Executive Board Member                          Nov. 2011-June 2013 
University of California, Irvine, CA  
• Member of the executive board that manages and maintains an 
organization with over 60 chapter members  
• Organized the Comedy Show for Breast Cancer fundraiser, which 
resulted in raising over $6000 and proceeds donated to the American 
Cancer Society 
• Organized a philanthropic  effort that contributed 500 total volunteer 
hours with the Boys and Girls Club of America  
 
American Leadership Academy                                 April 2010  
Cabo San Lucas, MX            
• Participated in 7 seminars developing leadership, communication, and 
commitment skills 
• Participated in team-building exercises with successful and dynamic 
leaders in business, law, public service, education, science & 
technology, and sports 
• Planned and implemented a lecture, titled “Learn, Return, & Lead” for 
over 100 undergraduate students to increase involvement in leadership 
on & off campus 
 
EMPLOYMENT 
 
Anteater Recreation Center                            Oct. 2009- Jan. 2012 
Fitlab Employee 
University of California, Irvine, CA 
• CPR and First Aid certified to ensure safety and well being of patrons in 
the weight rooms 
• Trained incoming staff to exhibit strong patron relations by emphasizing 
personal communication skills as well taking initiative in work duties 
• Maintained a comfortable and optimal environment in the gym by 
cleaning equipment and organization of weight equipment 
 
HONORS & AWARDS 
 
Douglas White Oaks Ranch Scholarship                                     Summer 2009 
 The Boeing Company, El Segundo, CA 
• Recipient of $5000 scholarship in recognition of leadership and 
academia 
 
Dean’s Honor List                          2011-2012 
University of California, Irvine, CA 
• Received Dean’s Honor List fall, winter, and spring quarter of junior year, 
and winter quarter of senior year 
